HERPLEX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jun 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HERPLEX is an ophthalmic solution approved in 1963 for the treatment of herpes simplex keratitis and other viral eye infections. The small-molecule formulation is administered as topical eye drops. Mechanism of action details are not currently available in the dataset.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential team consolidation or strategic repositioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HERPLEX presents limited career growth opportunities due to its mature lifecycle stage and approaching loss of exclusivity. Roles focused on this product typically emphasize operational maintenance and defensive market positioning rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on HERPLEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.